BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Steminent Biotherapeutics Inc.

Company Info

Name /Steminent Biotherapeutics Inc.

Address /No. 16, Wenhu St., Neihu Dist., Taipei City, Taiwan

Website /www.steminent.com

Presenter

Name /Kevin Ho

Title /Director

Email /kevinho@steminent.com

Telephone /(Work) +886-2-26279216 ext.670

Fax /+886-2-26276455

Mobile /

Company Type

Biotechnology

About the Company

Steminent Biotherapeutics Inc. is a global leading stem cell biotechnology company focusing on the clinical development and commercialization of Stemchyaml®, Steminent’s proprietary standardized allogeneic mesenchymal stem/stromal cell product.

Brief Description of main products or services

The Stemchymal® is a standardized allogeneic stem cell product from human adipose tissues. The lead program of Stemchymal® treatment is conducting its phase 2 trial in US, Japan (with partner) and has completed its phase 2 trial in Taiwan for spinocerebellar ataxia. Stemchyaml® is granted Spinocerebellar Ataxia orphan drug designation from FDA and PMDA.

Manufactured by Steminent’s proprietary technology platform, Stemchymal® possesses unique therapeutic advantages including:

  • High homogeneity
  • Superior immunomodulatory ability – rely on Stemchyaml®’s unique functional surface marker pattern.
  • Versatile paracrine/endocrine ability – Stemchyaml® possesses superior expression profile of key cytokines and growth factors.
  • Multipotent differentiation ability – Stemchymal® cells possess genuine capability of stem cells.

With its superior safety, Stemchymal® has been accumulated its scientific evidence and shown great therapeutic potential for spinocerebellar ataxia and neurodegenerative diseases.

Contact Person

Name /Kevin Ho

Email /kevinho@steminent.com

Phone /(Work) +886-2-26279216 ext.670